JENA, Germany, March 13, 2026 — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical firm at the forefront of developing anti-inflammatory therapies by targeting the complement system, today disclosed that it has received a written notification (the “Notice”), dated March 11, 2026, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”). This Notice indicates that, over the past thirty (30) consecutive business days, the closing bid price for the Company’s ordinary shares fell below the $1.00 per share minimum required for continued listing on Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Rule”).
Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted an initial 180-calendar-day period, concluding on September 7, 2026, to restore compliance. If the Company fails to meet the Minimum Bid Price Rule within this timeframe, it may explore applying to transfer its securities from The Nasdaq Global Select Market to The Nasdaq Capital Market. This transfer is contingent on the Company satisfying the applicable market value of publicly held shares needed for continued listing, as well as all other initial listing requirements for The Nasdaq Capital Market (excluding the bid price requirement). Such a transfer would afford the Company an additional 180 calendar days, through March 8, 2027, to regain compliance. There is no guarantee the Company would qualify for this extended 180-calendar-day compliance period, if applicable, or that Nasdaq staff would approve the request for continued listing.
The Notice does not immediately impact the listing or trading of the Company’s ordinary shares. The Company intends to track the bid price of its common shares and evaluate available strategies to achieve compliance with the Minimum Bid Price Rule.
About InflaRx N.V.
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company leading the development of anti-inflammatory therapies. It leverages its proprietary anti-C5a and anti-C5aR technologies to discover, develop, and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a potent inflammatory mediator involved in the progression of numerous inflammatory conditions. InflaRx’s lead program is izicopan (INF904), an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor. This compound has demonstrated promising pharmacokinetic/pharmacodynamic (PK/PD) properties and therapeutic potential in Phase 1 and Phase 2a clinical trials. The company is advancing izicopan for the treatment of several inflammatory diseases, including hidradenitis suppurativa (HS). Additionally, InflaRx has developed vilobelimab, a novel, intravenously delivered, first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a. Vilobelimab has shown disease-modifying clinical activity and tolerability in multiple clinical studies.
InflaRx was established in 2007, with group offices and subsidiaries located in Jena and Munich, Germany, and Ann Arbor, MI, USA. For more information, visit www.inflarx.de. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (collectively referred to as InflaRx).
Contacts:
| InflaRx N.V. | MC Services AG |
| Jan Medina, CFA Vice President, Head of Investor Relations Email:IR@inflarx.de |
Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email:inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752 |
FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. All statements beyond those of historical fact are forward-looking, often identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential,” or “continue,” including statements about our compliance with the Minimum Bid Price Rule and the listing or trading of our ordinary shares. Forward-looking statements appear throughout this release and may cover our intentions, beliefs, projections, outlook, analyses, current expectations, and the risks, uncertainties, and other factors discussed under the headings “Risk factors” and “Cautionary statement regarding forward looking statements” in our periodic SEC filings. These statements are only valid as of the date of this press release and involve known and unknown risks, uncertainties, and other significant factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. Given these risks and uncertainties, undue reliance should not be placed on these forward-looking statements, and we assume no obligation to update them, even if new information becomes available, except as required by law.